Clinical TrialAug 6, 2026, 08:35 AM
Propanc PRP Shows >90% Tumor Inhibition in Pancreatic Cancer Models
AI Summary
Propanc Biopharma announced compelling new preclinical and translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC). The data showed over 90% mean tumor growth inhibition and a more than 2.5-fold extension in median overall survival in advanced PDAC models. The company is accelerating its Phase 1b, First-In-Human study in advanced solid tumors, with a clinical trial application expected in Australia in the coming months.
Key Highlights
- PRP achieved >90% mean tumor growth inhibition in PDAC models.
- PRP extended median overall survival by more than 2.5-fold in treated animals.
- PRP significantly reduced metastatic burden in liver and peritoneum.
- Company accelerating Phase 1b, First-In-Human study in 30-40 patients.
- Clinical trial application for Australia expected in coming months.
- USFDA previously granted Orphan Drug Designation for PRP in pancreatic cancer.
- GMP production for PRP is targeted for late 2026.
Price Impact
More from PPCB